{"id":6432,"date":"2020-11-26T16:19:22","date_gmt":"2020-11-26T20:19:22","guid":{"rendered":"http:\/\/miunidad.eu\/purib3\/?p=6432"},"modified":"2022-09-16T11:41:16","modified_gmt":"2022-09-16T09:41:16","slug":"ace-de-tofacitinib-presentado-en-la-reunion-anual-de-aeg","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/ace-de-tofacitinib-presentado-en-la-reunion-anual-de-aeg\/","title":{"rendered":"ACE de Tofacitinib presentado en la Reuni\u00f3n Anual de AEG"},"content":{"rendered":"<div class=\"col80p\">\n<p>PORIB ha presentado la comunicaci\u00f3n <strong>\u201cAn\u00e1lisis coste-efectividad del uso de tofacitinib frente a vedolizumab para el tratamiento de la colitis ulcerosa activa de moderada a grave en Espa\u00f1a\u201d,<\/strong> de los autores Taxonera C, de Andr\u00e9s-Nogales F, Garc\u00eda S, S\u00e1nchez-Guerrero A, Menchen B, Peral C, C\u00e1bez A, G\u00f3mez S, L\u00f3pez Ib\u00e1\u00f1ez-Aldecoa A, Casado M\u00c1, Mench\u00e9n L, en la\u00a0XXIII Reuni\u00f3n Anual de la Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda (AEG) celebrada del 5 al 6 de noviembre.<\/p>\n<p>El objetivo de la Comunicaci\u00f3n era evaluar, desde la perspectiva del Sistema Nacional de Salud (SNS) Espa\u00f1ol, la eficiencia del uso de tofacitinib frente a vedolizumab en el tratamiento de la colitis ulcerosa (CU) activa de moderada a grave en dos subpoblaciones de pacientes: tras fallo o intolerancia a terapia convencional (bio-na\u00efve) y tras fallo o intolerancia a tratamiento con un f\u00e1rmaco biol\u00f3gico (bio-experienced).<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PORIB ha presentado la comunicaci\u00f3n \u201cAn\u00e1lisis coste-efectividad del uso de tofacitinib frente a vedolizumab para el tratamiento de la colitis ulcerosa activa de moderada a grave en Espa\u00f1a\u201d, de los autores Taxonera C, de Andr\u00e9s-Nogales F, Garc\u00eda S, S\u00e1nchez-Guerrero A, Menchen B, Peral C, C\u00e1bez A, G\u00f3mez S, L\u00f3pez Ib\u00e1\u00f1ez-Aldecoa A, Casado M\u00c1, Mench\u00e9n L,&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/ace-de-tofacitinib-presentado-en-la-reunion-anual-de-aeg\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":1,"featured_media":6433,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-6432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/6432"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=6432"}],"version-history":[{"count":2,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/6432\/revisions"}],"predecessor-version":[{"id":22479,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/6432\/revisions\/22479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/6433"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=6432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=6432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=6432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}